Global Indocyanine Green

Indocyanine Green Comprehensive Study by Application (Ophthalmology, Neurosurgery, Liver Diseases, Others), Dosage Consideration (Hepatic Impairment, Renal Impairment), End Users (Neonates and Infants, Children, Adults), Route of Administration (Intravenous Bolus Injection, Interstitial Cervical Injection) Players and Region - Global Market Outlook to 2028

Indocyanine Green Market by XX Submarkets | Forecast Years 2024-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Indocyanine green (ICG), cyanine dye that is used in medical diagnostics. It is used to determine cardiac output, hepatic function, liver and gastric blood flow, and for ophthalmic angiography. ICG has a top spectral absorption at about 800 nm. These IR frequencies penetrate retinal layers, permitting ICG angiography to image deeper patterns of circulation compared to fluorescein angiography. ICG fixes tightly to plasma proteins and becomes narrowed to the vascular system. It has a half-life of 150 to 180 seconds & is detached from circulation exclusively by the liver to bile juice. The increasing use in medical diagnostics is likely to impel the ICG market growth.

AttributesDetails
Study Period2018-2028
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledAkorn, Incorporated (United States), Aurolab (India), SERB (Belgium), Diagnostic Green GmbH (Germany), Daiichi Sankyo Company, Limited (Japan), Sigma-Aldrich Corporation (United States), Iris Biotech GmbH (Germany) and Pulsion Medical Systems (Germany)


This growth is primarily driven by Increasing usage in medical diagnostics and Growing number of patients undergoing ophthalmic angiography.

Globally, a noticeable market trend is evident Consumer Increasing Health Care Spending Major Vendors, such as Akorn, Incorporated (United States), Aurolab (India), SERB (Belgium), Diagnostic Green GmbH (Germany), Daiichi Sankyo Company, Limited (Japan), Sigma-Aldrich Corporation (United States), Iris Biotech GmbH (Germany) and Pulsion Medical Systems (Germany), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Regulatory Insights:
“In United States, The Food and Drug Administration (FDA) regulates indocyanine green. FDA has determined that IC-GREEN (indocyanine green for injection), 10 milligrams (mg)/vial, 40 mg/vial, and 50 mg/vial, was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for indocyanine green for injection, 10 mg/vial, 40 mg/vial, and 50 mg/vial if all other legal and regulatory requirements are met.”

Influencing Trend:
Consumer Increasing Health Care Spending

Market Growth Drivers:
Increasing usage in medical diagnostics and Growing number of patients undergoing ophthalmic angiography

Restraints:
Anaphylaxis or other allergic reactions occurrence in patients with iodine hypersensitivity

Opportunities:
Growing healthcare industry and Increasing Opportunities in developing economies

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Vendors landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Indocyanine Green Market
- Analysis about New Entrants in Indocyanine Green Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Indocyanine Green Study Sheds Light on
— The Indocyanine Green Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Indocyanine Green industry Vendors. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Indocyanine Green industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Vendors can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Application
  • Ophthalmology
  • Neurosurgery
  • Liver Diseases
  • Others
By Dosage Consideration
  • Hepatic Impairment
  • Renal Impairment

By End Users
  • Neonates and Infants
  • Children
  • Adults

By Route of Administration
  • Intravenous Bolus Injection
  • Interstitial Cervical Injection

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing usage in medical diagnostics
      • 3.2.2. Growing number of patients undergoing ophthalmic angiography
    • 3.3. Market Trends
      • 3.3.1. Consumer Increasing Health Care Spending
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Indocyanine Green, by Application, Dosage Consideration, End Users, Route of Administration and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Indocyanine Green (Value)
      • 5.2.1. Global Indocyanine Green by: Application (Value)
        • 5.2.1.1. Ophthalmology
        • 5.2.1.2. Neurosurgery
        • 5.2.1.3. Liver Diseases
        • 5.2.1.4. Others
      • 5.2.2. Global Indocyanine Green by: Dosage Consideration (Value)
        • 5.2.2.1. Hepatic Impairment
        • 5.2.2.2. Renal Impairment
      • 5.2.3. Global Indocyanine Green by: End Users (Value)
        • 5.2.3.1. Neonates and Infants
        • 5.2.3.2. Children
        • 5.2.3.3. Adults
      • 5.2.4. Global Indocyanine Green by: Route of Administration (Value)
        • 5.2.4.1. Intravenous Bolus Injection
        • 5.2.4.2. Interstitial Cervical Injection
      • 5.2.5. Global Indocyanine Green Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Indocyanine Green (Volume)
      • 5.3.1. Global Indocyanine Green by: Application (Volume)
        • 5.3.1.1. Ophthalmology
        • 5.3.1.2. Neurosurgery
        • 5.3.1.3. Liver Diseases
        • 5.3.1.4. Others
      • 5.3.2. Global Indocyanine Green by: Dosage Consideration (Volume)
        • 5.3.2.1. Hepatic Impairment
        • 5.3.2.2. Renal Impairment
      • 5.3.3. Global Indocyanine Green by: End Users (Volume)
        • 5.3.3.1. Neonates and Infants
        • 5.3.3.2. Children
        • 5.3.3.3. Adults
      • 5.3.4. Global Indocyanine Green by: Route of Administration (Volume)
        • 5.3.4.1. Intravenous Bolus Injection
        • 5.3.4.2. Interstitial Cervical Injection
      • 5.3.5. Global Indocyanine Green Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Indocyanine Green (Price)
  • 6. Indocyanine Green: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Akorn, Incorporated (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Aurolab (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. SERB (Belgium)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Diagnostic Green GmbH (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Daiichi Sankyo Company, Limited (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sigma-Aldrich Corporation (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Iris Biotech GmbH (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pulsion Medical Systems (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Indocyanine Green Sale, by Application, Dosage Consideration, End Users, Route of Administration and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Indocyanine Green (Value)
      • 7.2.1. Global Indocyanine Green by: Application (Value)
        • 7.2.1.1. Ophthalmology
        • 7.2.1.2. Neurosurgery
        • 7.2.1.3. Liver Diseases
        • 7.2.1.4. Others
      • 7.2.2. Global Indocyanine Green by: Dosage Consideration (Value)
        • 7.2.2.1. Hepatic Impairment
        • 7.2.2.2. Renal Impairment
      • 7.2.3. Global Indocyanine Green by: End Users (Value)
        • 7.2.3.1. Neonates and Infants
        • 7.2.3.2. Children
        • 7.2.3.3. Adults
      • 7.2.4. Global Indocyanine Green by: Route of Administration (Value)
        • 7.2.4.1. Intravenous Bolus Injection
        • 7.2.4.2. Interstitial Cervical Injection
      • 7.2.5. Global Indocyanine Green Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Indocyanine Green (Volume)
      • 7.3.1. Global Indocyanine Green by: Application (Volume)
        • 7.3.1.1. Ophthalmology
        • 7.3.1.2. Neurosurgery
        • 7.3.1.3. Liver Diseases
        • 7.3.1.4. Others
      • 7.3.2. Global Indocyanine Green by: Dosage Consideration (Volume)
        • 7.3.2.1. Hepatic Impairment
        • 7.3.2.2. Renal Impairment
      • 7.3.3. Global Indocyanine Green by: End Users (Volume)
        • 7.3.3.1. Neonates and Infants
        • 7.3.3.2. Children
        • 7.3.3.3. Adults
      • 7.3.4. Global Indocyanine Green by: Route of Administration (Volume)
        • 7.3.4.1. Intravenous Bolus Injection
        • 7.3.4.2. Interstitial Cervical Injection
      • 7.3.5. Global Indocyanine Green Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Indocyanine Green (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Indocyanine Green: by Application(USD Million)
  • Table 2. Indocyanine Green Ophthalmology , by Region USD Million (2018-2023)
  • Table 3. Indocyanine Green Neurosurgery , by Region USD Million (2018-2023)
  • Table 4. Indocyanine Green Liver Diseases , by Region USD Million (2018-2023)
  • Table 5. Indocyanine Green Others , by Region USD Million (2018-2023)
  • Table 6. Indocyanine Green: by Dosage Consideration(USD Million)
  • Table 7. Indocyanine Green Hepatic Impairment , by Region USD Million (2018-2023)
  • Table 8. Indocyanine Green Renal Impairment , by Region USD Million (2018-2023)
  • Table 9. Indocyanine Green: by End Users(USD Million)
  • Table 10. Indocyanine Green Neonates and Infants , by Region USD Million (2018-2023)
  • Table 11. Indocyanine Green Children , by Region USD Million (2018-2023)
  • Table 12. Indocyanine Green Adults , by Region USD Million (2018-2023)
  • Table 13. Indocyanine Green: by Route of Administration(USD Million)
  • Table 14. Indocyanine Green Intravenous Bolus Injection , by Region USD Million (2018-2023)
  • Table 15. Indocyanine Green Interstitial Cervical Injection , by Region USD Million (2018-2023)
  • Table 16. South America Indocyanine Green, by Country USD Million (2018-2023)
  • Table 17. South America Indocyanine Green, by Application USD Million (2018-2023)
  • Table 18. South America Indocyanine Green, by Dosage Consideration USD Million (2018-2023)
  • Table 19. South America Indocyanine Green, by End Users USD Million (2018-2023)
  • Table 20. South America Indocyanine Green, by Route of Administration USD Million (2018-2023)
  • Table 21. Brazil Indocyanine Green, by Application USD Million (2018-2023)
  • Table 22. Brazil Indocyanine Green, by Dosage Consideration USD Million (2018-2023)
  • Table 23. Brazil Indocyanine Green, by End Users USD Million (2018-2023)
  • Table 24. Brazil Indocyanine Green, by Route of Administration USD Million (2018-2023)
  • Table 25. Argentina Indocyanine Green, by Application USD Million (2018-2023)
  • Table 26. Argentina Indocyanine Green, by Dosage Consideration USD Million (2018-2023)
  • Table 27. Argentina Indocyanine Green, by End Users USD Million (2018-2023)
  • Table 28. Argentina Indocyanine Green, by Route of Administration USD Million (2018-2023)
  • Table 29. Rest of South America Indocyanine Green, by Application USD Million (2018-2023)
  • Table 30. Rest of South America Indocyanine Green, by Dosage Consideration USD Million (2018-2023)
  • Table 31. Rest of South America Indocyanine Green, by End Users USD Million (2018-2023)
  • Table 32. Rest of South America Indocyanine Green, by Route of Administration USD Million (2018-2023)
  • Table 33. Asia Pacific Indocyanine Green, by Country USD Million (2018-2023)
  • Table 34. Asia Pacific Indocyanine Green, by Application USD Million (2018-2023)
  • Table 35. Asia Pacific Indocyanine Green, by Dosage Consideration USD Million (2018-2023)
  • Table 36. Asia Pacific Indocyanine Green, by End Users USD Million (2018-2023)
  • Table 37. Asia Pacific Indocyanine Green, by Route of Administration USD Million (2018-2023)
  • Table 38. China Indocyanine Green, by Application USD Million (2018-2023)
  • Table 39. China Indocyanine Green, by Dosage Consideration USD Million (2018-2023)
  • Table 40. China Indocyanine Green, by End Users USD Million (2018-2023)
  • Table 41. China Indocyanine Green, by Route of Administration USD Million (2018-2023)
  • Table 42. Japan Indocyanine Green, by Application USD Million (2018-2023)
  • Table 43. Japan Indocyanine Green, by Dosage Consideration USD Million (2018-2023)
  • Table 44. Japan Indocyanine Green, by End Users USD Million (2018-2023)
  • Table 45. Japan Indocyanine Green, by Route of Administration USD Million (2018-2023)
  • Table 46. India Indocyanine Green, by Application USD Million (2018-2023)
  • Table 47. India Indocyanine Green, by Dosage Consideration USD Million (2018-2023)
  • Table 48. India Indocyanine Green, by End Users USD Million (2018-2023)
  • Table 49. India Indocyanine Green, by Route of Administration USD Million (2018-2023)
  • Table 50. South Korea Indocyanine Green, by Application USD Million (2018-2023)
  • Table 51. South Korea Indocyanine Green, by Dosage Consideration USD Million (2018-2023)
  • Table 52. South Korea Indocyanine Green, by End Users USD Million (2018-2023)
  • Table 53. South Korea Indocyanine Green, by Route of Administration USD Million (2018-2023)
  • Table 54. Taiwan Indocyanine Green, by Application USD Million (2018-2023)
  • Table 55. Taiwan Indocyanine Green, by Dosage Consideration USD Million (2018-2023)
  • Table 56. Taiwan Indocyanine Green, by End Users USD Million (2018-2023)
  • Table 57. Taiwan Indocyanine Green, by Route of Administration USD Million (2018-2023)
  • Table 58. Australia Indocyanine Green, by Application USD Million (2018-2023)
  • Table 59. Australia Indocyanine Green, by Dosage Consideration USD Million (2018-2023)
  • Table 60. Australia Indocyanine Green, by End Users USD Million (2018-2023)
  • Table 61. Australia Indocyanine Green, by Route of Administration USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Indocyanine Green, by Application USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Indocyanine Green, by Dosage Consideration USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Indocyanine Green, by End Users USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Indocyanine Green, by Route of Administration USD Million (2018-2023)
  • Table 66. Europe Indocyanine Green, by Country USD Million (2018-2023)
  • Table 67. Europe Indocyanine Green, by Application USD Million (2018-2023)
  • Table 68. Europe Indocyanine Green, by Dosage Consideration USD Million (2018-2023)
  • Table 69. Europe Indocyanine Green, by End Users USD Million (2018-2023)
  • Table 70. Europe Indocyanine Green, by Route of Administration USD Million (2018-2023)
  • Table 71. Germany Indocyanine Green, by Application USD Million (2018-2023)
  • Table 72. Germany Indocyanine Green, by Dosage Consideration USD Million (2018-2023)
  • Table 73. Germany Indocyanine Green, by End Users USD Million (2018-2023)
  • Table 74. Germany Indocyanine Green, by Route of Administration USD Million (2018-2023)
  • Table 75. France Indocyanine Green, by Application USD Million (2018-2023)
  • Table 76. France Indocyanine Green, by Dosage Consideration USD Million (2018-2023)
  • Table 77. France Indocyanine Green, by End Users USD Million (2018-2023)
  • Table 78. France Indocyanine Green, by Route of Administration USD Million (2018-2023)
  • Table 79. Italy Indocyanine Green, by Application USD Million (2018-2023)
  • Table 80. Italy Indocyanine Green, by Dosage Consideration USD Million (2018-2023)
  • Table 81. Italy Indocyanine Green, by End Users USD Million (2018-2023)
  • Table 82. Italy Indocyanine Green, by Route of Administration USD Million (2018-2023)
  • Table 83. United Kingdom Indocyanine Green, by Application USD Million (2018-2023)
  • Table 84. United Kingdom Indocyanine Green, by Dosage Consideration USD Million (2018-2023)
  • Table 85. United Kingdom Indocyanine Green, by End Users USD Million (2018-2023)
  • Table 86. United Kingdom Indocyanine Green, by Route of Administration USD Million (2018-2023)
  • Table 87. Netherlands Indocyanine Green, by Application USD Million (2018-2023)
  • Table 88. Netherlands Indocyanine Green, by Dosage Consideration USD Million (2018-2023)
  • Table 89. Netherlands Indocyanine Green, by End Users USD Million (2018-2023)
  • Table 90. Netherlands Indocyanine Green, by Route of Administration USD Million (2018-2023)
  • Table 91. Rest of Europe Indocyanine Green, by Application USD Million (2018-2023)
  • Table 92. Rest of Europe Indocyanine Green, by Dosage Consideration USD Million (2018-2023)
  • Table 93. Rest of Europe Indocyanine Green, by End Users USD Million (2018-2023)
  • Table 94. Rest of Europe Indocyanine Green, by Route of Administration USD Million (2018-2023)
  • Table 95. MEA Indocyanine Green, by Country USD Million (2018-2023)
  • Table 96. MEA Indocyanine Green, by Application USD Million (2018-2023)
  • Table 97. MEA Indocyanine Green, by Dosage Consideration USD Million (2018-2023)
  • Table 98. MEA Indocyanine Green, by End Users USD Million (2018-2023)
  • Table 99. MEA Indocyanine Green, by Route of Administration USD Million (2018-2023)
  • Table 100. Middle East Indocyanine Green, by Application USD Million (2018-2023)
  • Table 101. Middle East Indocyanine Green, by Dosage Consideration USD Million (2018-2023)
  • Table 102. Middle East Indocyanine Green, by End Users USD Million (2018-2023)
  • Table 103. Middle East Indocyanine Green, by Route of Administration USD Million (2018-2023)
  • Table 104. Africa Indocyanine Green, by Application USD Million (2018-2023)
  • Table 105. Africa Indocyanine Green, by Dosage Consideration USD Million (2018-2023)
  • Table 106. Africa Indocyanine Green, by End Users USD Million (2018-2023)
  • Table 107. Africa Indocyanine Green, by Route of Administration USD Million (2018-2023)
  • Table 108. North America Indocyanine Green, by Country USD Million (2018-2023)
  • Table 109. North America Indocyanine Green, by Application USD Million (2018-2023)
  • Table 110. North America Indocyanine Green, by Dosage Consideration USD Million (2018-2023)
  • Table 111. North America Indocyanine Green, by End Users USD Million (2018-2023)
  • Table 112. North America Indocyanine Green, by Route of Administration USD Million (2018-2023)
  • Table 113. United States Indocyanine Green, by Application USD Million (2018-2023)
  • Table 114. United States Indocyanine Green, by Dosage Consideration USD Million (2018-2023)
  • Table 115. United States Indocyanine Green, by End Users USD Million (2018-2023)
  • Table 116. United States Indocyanine Green, by Route of Administration USD Million (2018-2023)
  • Table 117. Canada Indocyanine Green, by Application USD Million (2018-2023)
  • Table 118. Canada Indocyanine Green, by Dosage Consideration USD Million (2018-2023)
  • Table 119. Canada Indocyanine Green, by End Users USD Million (2018-2023)
  • Table 120. Canada Indocyanine Green, by Route of Administration USD Million (2018-2023)
  • Table 121. Mexico Indocyanine Green, by Application USD Million (2018-2023)
  • Table 122. Mexico Indocyanine Green, by Dosage Consideration USD Million (2018-2023)
  • Table 123. Mexico Indocyanine Green, by End Users USD Million (2018-2023)
  • Table 124. Mexico Indocyanine Green, by Route of Administration USD Million (2018-2023)
  • Table 125. Indocyanine Green Sales: by Application(K Tons)
  • Table 126. Indocyanine Green Sales Ophthalmology , by Region K Tons (2018-2023)
  • Table 127. Indocyanine Green Sales Neurosurgery , by Region K Tons (2018-2023)
  • Table 128. Indocyanine Green Sales Liver Diseases , by Region K Tons (2018-2023)
  • Table 129. Indocyanine Green Sales Others , by Region K Tons (2018-2023)
  • Table 130. Indocyanine Green Sales: by Dosage Consideration(K Tons)
  • Table 131. Indocyanine Green Sales Hepatic Impairment , by Region K Tons (2018-2023)
  • Table 132. Indocyanine Green Sales Renal Impairment , by Region K Tons (2018-2023)
  • Table 133. Indocyanine Green Sales: by End Users(K Tons)
  • Table 134. Indocyanine Green Sales Neonates and Infants , by Region K Tons (2018-2023)
  • Table 135. Indocyanine Green Sales Children , by Region K Tons (2018-2023)
  • Table 136. Indocyanine Green Sales Adults , by Region K Tons (2018-2023)
  • Table 137. Indocyanine Green Sales: by Route of Administration(K Tons)
  • Table 138. Indocyanine Green Sales Intravenous Bolus Injection , by Region K Tons (2018-2023)
  • Table 139. Indocyanine Green Sales Interstitial Cervical Injection , by Region K Tons (2018-2023)
  • Table 140. South America Indocyanine Green Sales, by Country K Tons (2018-2023)
  • Table 141. South America Indocyanine Green Sales, by Application K Tons (2018-2023)
  • Table 142. South America Indocyanine Green Sales, by Dosage Consideration K Tons (2018-2023)
  • Table 143. South America Indocyanine Green Sales, by End Users K Tons (2018-2023)
  • Table 144. South America Indocyanine Green Sales, by Route of Administration K Tons (2018-2023)
  • Table 145. Brazil Indocyanine Green Sales, by Application K Tons (2018-2023)
  • Table 146. Brazil Indocyanine Green Sales, by Dosage Consideration K Tons (2018-2023)
  • Table 147. Brazil Indocyanine Green Sales, by End Users K Tons (2018-2023)
  • Table 148. Brazil Indocyanine Green Sales, by Route of Administration K Tons (2018-2023)
  • Table 149. Argentina Indocyanine Green Sales, by Application K Tons (2018-2023)
  • Table 150. Argentina Indocyanine Green Sales, by Dosage Consideration K Tons (2018-2023)
  • Table 151. Argentina Indocyanine Green Sales, by End Users K Tons (2018-2023)
  • Table 152. Argentina Indocyanine Green Sales, by Route of Administration K Tons (2018-2023)
  • Table 153. Rest of South America Indocyanine Green Sales, by Application K Tons (2018-2023)
  • Table 154. Rest of South America Indocyanine Green Sales, by Dosage Consideration K Tons (2018-2023)
  • Table 155. Rest of South America Indocyanine Green Sales, by End Users K Tons (2018-2023)
  • Table 156. Rest of South America Indocyanine Green Sales, by Route of Administration K Tons (2018-2023)
  • Table 157. Asia Pacific Indocyanine Green Sales, by Country K Tons (2018-2023)
  • Table 158. Asia Pacific Indocyanine Green Sales, by Application K Tons (2018-2023)
  • Table 159. Asia Pacific Indocyanine Green Sales, by Dosage Consideration K Tons (2018-2023)
  • Table 160. Asia Pacific Indocyanine Green Sales, by End Users K Tons (2018-2023)
  • Table 161. Asia Pacific Indocyanine Green Sales, by Route of Administration K Tons (2018-2023)
  • Table 162. China Indocyanine Green Sales, by Application K Tons (2018-2023)
  • Table 163. China Indocyanine Green Sales, by Dosage Consideration K Tons (2018-2023)
  • Table 164. China Indocyanine Green Sales, by End Users K Tons (2018-2023)
  • Table 165. China Indocyanine Green Sales, by Route of Administration K Tons (2018-2023)
  • Table 166. Japan Indocyanine Green Sales, by Application K Tons (2018-2023)
  • Table 167. Japan Indocyanine Green Sales, by Dosage Consideration K Tons (2018-2023)
  • Table 168. Japan Indocyanine Green Sales, by End Users K Tons (2018-2023)
  • Table 169. Japan Indocyanine Green Sales, by Route of Administration K Tons (2018-2023)
  • Table 170. India Indocyanine Green Sales, by Application K Tons (2018-2023)
  • Table 171. India Indocyanine Green Sales, by Dosage Consideration K Tons (2018-2023)
  • Table 172. India Indocyanine Green Sales, by End Users K Tons (2018-2023)
  • Table 173. India Indocyanine Green Sales, by Route of Administration K Tons (2018-2023)
  • Table 174. South Korea Indocyanine Green Sales, by Application K Tons (2018-2023)
  • Table 175. South Korea Indocyanine Green Sales, by Dosage Consideration K Tons (2018-2023)
  • Table 176. South Korea Indocyanine Green Sales, by End Users K Tons (2018-2023)
  • Table 177. South Korea Indocyanine Green Sales, by Route of Administration K Tons (2018-2023)
  • Table 178. Taiwan Indocyanine Green Sales, by Application K Tons (2018-2023)
  • Table 179. Taiwan Indocyanine Green Sales, by Dosage Consideration K Tons (2018-2023)
  • Table 180. Taiwan Indocyanine Green Sales, by End Users K Tons (2018-2023)
  • Table 181. Taiwan Indocyanine Green Sales, by Route of Administration K Tons (2018-2023)
  • Table 182. Australia Indocyanine Green Sales, by Application K Tons (2018-2023)
  • Table 183. Australia Indocyanine Green Sales, by Dosage Consideration K Tons (2018-2023)
  • Table 184. Australia Indocyanine Green Sales, by End Users K Tons (2018-2023)
  • Table 185. Australia Indocyanine Green Sales, by Route of Administration K Tons (2018-2023)
  • Table 186. Rest of Asia-Pacific Indocyanine Green Sales, by Application K Tons (2018-2023)
  • Table 187. Rest of Asia-Pacific Indocyanine Green Sales, by Dosage Consideration K Tons (2018-2023)
  • Table 188. Rest of Asia-Pacific Indocyanine Green Sales, by End Users K Tons (2018-2023)
  • Table 189. Rest of Asia-Pacific Indocyanine Green Sales, by Route of Administration K Tons (2018-2023)
  • Table 190. Europe Indocyanine Green Sales, by Country K Tons (2018-2023)
  • Table 191. Europe Indocyanine Green Sales, by Application K Tons (2018-2023)
  • Table 192. Europe Indocyanine Green Sales, by Dosage Consideration K Tons (2018-2023)
  • Table 193. Europe Indocyanine Green Sales, by End Users K Tons (2018-2023)
  • Table 194. Europe Indocyanine Green Sales, by Route of Administration K Tons (2018-2023)
  • Table 195. Germany Indocyanine Green Sales, by Application K Tons (2018-2023)
  • Table 196. Germany Indocyanine Green Sales, by Dosage Consideration K Tons (2018-2023)
  • Table 197. Germany Indocyanine Green Sales, by End Users K Tons (2018-2023)
  • Table 198. Germany Indocyanine Green Sales, by Route of Administration K Tons (2018-2023)
  • Table 199. France Indocyanine Green Sales, by Application K Tons (2018-2023)
  • Table 200. France Indocyanine Green Sales, by Dosage Consideration K Tons (2018-2023)
  • Table 201. France Indocyanine Green Sales, by End Users K Tons (2018-2023)
  • Table 202. France Indocyanine Green Sales, by Route of Administration K Tons (2018-2023)
  • Table 203. Italy Indocyanine Green Sales, by Application K Tons (2018-2023)
  • Table 204. Italy Indocyanine Green Sales, by Dosage Consideration K Tons (2018-2023)
  • Table 205. Italy Indocyanine Green Sales, by End Users K Tons (2018-2023)
  • Table 206. Italy Indocyanine Green Sales, by Route of Administration K Tons (2018-2023)
  • Table 207. United Kingdom Indocyanine Green Sales, by Application K Tons (2018-2023)
  • Table 208. United Kingdom Indocyanine Green Sales, by Dosage Consideration K Tons (2018-2023)
  • Table 209. United Kingdom Indocyanine Green Sales, by End Users K Tons (2018-2023)
  • Table 210. United Kingdom Indocyanine Green Sales, by Route of Administration K Tons (2018-2023)
  • Table 211. Netherlands Indocyanine Green Sales, by Application K Tons (2018-2023)
  • Table 212. Netherlands Indocyanine Green Sales, by Dosage Consideration K Tons (2018-2023)
  • Table 213. Netherlands Indocyanine Green Sales, by End Users K Tons (2018-2023)
  • Table 214. Netherlands Indocyanine Green Sales, by Route of Administration K Tons (2018-2023)
  • Table 215. Rest of Europe Indocyanine Green Sales, by Application K Tons (2018-2023)
  • Table 216. Rest of Europe Indocyanine Green Sales, by Dosage Consideration K Tons (2018-2023)
  • Table 217. Rest of Europe Indocyanine Green Sales, by End Users K Tons (2018-2023)
  • Table 218. Rest of Europe Indocyanine Green Sales, by Route of Administration K Tons (2018-2023)
  • Table 219. MEA Indocyanine Green Sales, by Country K Tons (2018-2023)
  • Table 220. MEA Indocyanine Green Sales, by Application K Tons (2018-2023)
  • Table 221. MEA Indocyanine Green Sales, by Dosage Consideration K Tons (2018-2023)
  • Table 222. MEA Indocyanine Green Sales, by End Users K Tons (2018-2023)
  • Table 223. MEA Indocyanine Green Sales, by Route of Administration K Tons (2018-2023)
  • Table 224. Middle East Indocyanine Green Sales, by Application K Tons (2018-2023)
  • Table 225. Middle East Indocyanine Green Sales, by Dosage Consideration K Tons (2018-2023)
  • Table 226. Middle East Indocyanine Green Sales, by End Users K Tons (2018-2023)
  • Table 227. Middle East Indocyanine Green Sales, by Route of Administration K Tons (2018-2023)
  • Table 228. Africa Indocyanine Green Sales, by Application K Tons (2018-2023)
  • Table 229. Africa Indocyanine Green Sales, by Dosage Consideration K Tons (2018-2023)
  • Table 230. Africa Indocyanine Green Sales, by End Users K Tons (2018-2023)
  • Table 231. Africa Indocyanine Green Sales, by Route of Administration K Tons (2018-2023)
  • Table 232. North America Indocyanine Green Sales, by Country K Tons (2018-2023)
  • Table 233. North America Indocyanine Green Sales, by Application K Tons (2018-2023)
  • Table 234. North America Indocyanine Green Sales, by Dosage Consideration K Tons (2018-2023)
  • Table 235. North America Indocyanine Green Sales, by End Users K Tons (2018-2023)
  • Table 236. North America Indocyanine Green Sales, by Route of Administration K Tons (2018-2023)
  • Table 237. United States Indocyanine Green Sales, by Application K Tons (2018-2023)
  • Table 238. United States Indocyanine Green Sales, by Dosage Consideration K Tons (2018-2023)
  • Table 239. United States Indocyanine Green Sales, by End Users K Tons (2018-2023)
  • Table 240. United States Indocyanine Green Sales, by Route of Administration K Tons (2018-2023)
  • Table 241. Canada Indocyanine Green Sales, by Application K Tons (2018-2023)
  • Table 242. Canada Indocyanine Green Sales, by Dosage Consideration K Tons (2018-2023)
  • Table 243. Canada Indocyanine Green Sales, by End Users K Tons (2018-2023)
  • Table 244. Canada Indocyanine Green Sales, by Route of Administration K Tons (2018-2023)
  • Table 245. Mexico Indocyanine Green Sales, by Application K Tons (2018-2023)
  • Table 246. Mexico Indocyanine Green Sales, by Dosage Consideration K Tons (2018-2023)
  • Table 247. Mexico Indocyanine Green Sales, by End Users K Tons (2018-2023)
  • Table 248. Mexico Indocyanine Green Sales, by Route of Administration K Tons (2018-2023)
  • Table 249. Company Basic Information, Sales Area and Its Competitors
  • Table 250. Company Basic Information, Sales Area and Its Competitors
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Indocyanine Green: by Application(USD Million)
  • Table 258. Indocyanine Green Ophthalmology , by Region USD Million (2023-2028)
  • Table 259. Indocyanine Green Neurosurgery , by Region USD Million (2023-2028)
  • Table 260. Indocyanine Green Liver Diseases , by Region USD Million (2023-2028)
  • Table 261. Indocyanine Green Others , by Region USD Million (2023-2028)
  • Table 262. Indocyanine Green: by Dosage Consideration(USD Million)
  • Table 263. Indocyanine Green Hepatic Impairment , by Region USD Million (2023-2028)
  • Table 264. Indocyanine Green Renal Impairment , by Region USD Million (2023-2028)
  • Table 265. Indocyanine Green: by End Users(USD Million)
  • Table 266. Indocyanine Green Neonates and Infants , by Region USD Million (2023-2028)
  • Table 267. Indocyanine Green Children , by Region USD Million (2023-2028)
  • Table 268. Indocyanine Green Adults , by Region USD Million (2023-2028)
  • Table 269. Indocyanine Green: by Route of Administration(USD Million)
  • Table 270. Indocyanine Green Intravenous Bolus Injection , by Region USD Million (2023-2028)
  • Table 271. Indocyanine Green Interstitial Cervical Injection , by Region USD Million (2023-2028)
  • Table 272. South America Indocyanine Green, by Country USD Million (2023-2028)
  • Table 273. South America Indocyanine Green, by Application USD Million (2023-2028)
  • Table 274. South America Indocyanine Green, by Dosage Consideration USD Million (2023-2028)
  • Table 275. South America Indocyanine Green, by End Users USD Million (2023-2028)
  • Table 276. South America Indocyanine Green, by Route of Administration USD Million (2023-2028)
  • Table 277. Brazil Indocyanine Green, by Application USD Million (2023-2028)
  • Table 278. Brazil Indocyanine Green, by Dosage Consideration USD Million (2023-2028)
  • Table 279. Brazil Indocyanine Green, by End Users USD Million (2023-2028)
  • Table 280. Brazil Indocyanine Green, by Route of Administration USD Million (2023-2028)
  • Table 281. Argentina Indocyanine Green, by Application USD Million (2023-2028)
  • Table 282. Argentina Indocyanine Green, by Dosage Consideration USD Million (2023-2028)
  • Table 283. Argentina Indocyanine Green, by End Users USD Million (2023-2028)
  • Table 284. Argentina Indocyanine Green, by Route of Administration USD Million (2023-2028)
  • Table 285. Rest of South America Indocyanine Green, by Application USD Million (2023-2028)
  • Table 286. Rest of South America Indocyanine Green, by Dosage Consideration USD Million (2023-2028)
  • Table 287. Rest of South America Indocyanine Green, by End Users USD Million (2023-2028)
  • Table 288. Rest of South America Indocyanine Green, by Route of Administration USD Million (2023-2028)
  • Table 289. Asia Pacific Indocyanine Green, by Country USD Million (2023-2028)
  • Table 290. Asia Pacific Indocyanine Green, by Application USD Million (2023-2028)
  • Table 291. Asia Pacific Indocyanine Green, by Dosage Consideration USD Million (2023-2028)
  • Table 292. Asia Pacific Indocyanine Green, by End Users USD Million (2023-2028)
  • Table 293. Asia Pacific Indocyanine Green, by Route of Administration USD Million (2023-2028)
  • Table 294. China Indocyanine Green, by Application USD Million (2023-2028)
  • Table 295. China Indocyanine Green, by Dosage Consideration USD Million (2023-2028)
  • Table 296. China Indocyanine Green, by End Users USD Million (2023-2028)
  • Table 297. China Indocyanine Green, by Route of Administration USD Million (2023-2028)
  • Table 298. Japan Indocyanine Green, by Application USD Million (2023-2028)
  • Table 299. Japan Indocyanine Green, by Dosage Consideration USD Million (2023-2028)
  • Table 300. Japan Indocyanine Green, by End Users USD Million (2023-2028)
  • Table 301. Japan Indocyanine Green, by Route of Administration USD Million (2023-2028)
  • Table 302. India Indocyanine Green, by Application USD Million (2023-2028)
  • Table 303. India Indocyanine Green, by Dosage Consideration USD Million (2023-2028)
  • Table 304. India Indocyanine Green, by End Users USD Million (2023-2028)
  • Table 305. India Indocyanine Green, by Route of Administration USD Million (2023-2028)
  • Table 306. South Korea Indocyanine Green, by Application USD Million (2023-2028)
  • Table 307. South Korea Indocyanine Green, by Dosage Consideration USD Million (2023-2028)
  • Table 308. South Korea Indocyanine Green, by End Users USD Million (2023-2028)
  • Table 309. South Korea Indocyanine Green, by Route of Administration USD Million (2023-2028)
  • Table 310. Taiwan Indocyanine Green, by Application USD Million (2023-2028)
  • Table 311. Taiwan Indocyanine Green, by Dosage Consideration USD Million (2023-2028)
  • Table 312. Taiwan Indocyanine Green, by End Users USD Million (2023-2028)
  • Table 313. Taiwan Indocyanine Green, by Route of Administration USD Million (2023-2028)
  • Table 314. Australia Indocyanine Green, by Application USD Million (2023-2028)
  • Table 315. Australia Indocyanine Green, by Dosage Consideration USD Million (2023-2028)
  • Table 316. Australia Indocyanine Green, by End Users USD Million (2023-2028)
  • Table 317. Australia Indocyanine Green, by Route of Administration USD Million (2023-2028)
  • Table 318. Rest of Asia-Pacific Indocyanine Green, by Application USD Million (2023-2028)
  • Table 319. Rest of Asia-Pacific Indocyanine Green, by Dosage Consideration USD Million (2023-2028)
  • Table 320. Rest of Asia-Pacific Indocyanine Green, by End Users USD Million (2023-2028)
  • Table 321. Rest of Asia-Pacific Indocyanine Green, by Route of Administration USD Million (2023-2028)
  • Table 322. Europe Indocyanine Green, by Country USD Million (2023-2028)
  • Table 323. Europe Indocyanine Green, by Application USD Million (2023-2028)
  • Table 324. Europe Indocyanine Green, by Dosage Consideration USD Million (2023-2028)
  • Table 325. Europe Indocyanine Green, by End Users USD Million (2023-2028)
  • Table 326. Europe Indocyanine Green, by Route of Administration USD Million (2023-2028)
  • Table 327. Germany Indocyanine Green, by Application USD Million (2023-2028)
  • Table 328. Germany Indocyanine Green, by Dosage Consideration USD Million (2023-2028)
  • Table 329. Germany Indocyanine Green, by End Users USD Million (2023-2028)
  • Table 330. Germany Indocyanine Green, by Route of Administration USD Million (2023-2028)
  • Table 331. France Indocyanine Green, by Application USD Million (2023-2028)
  • Table 332. France Indocyanine Green, by Dosage Consideration USD Million (2023-2028)
  • Table 333. France Indocyanine Green, by End Users USD Million (2023-2028)
  • Table 334. France Indocyanine Green, by Route of Administration USD Million (2023-2028)
  • Table 335. Italy Indocyanine Green, by Application USD Million (2023-2028)
  • Table 336. Italy Indocyanine Green, by Dosage Consideration USD Million (2023-2028)
  • Table 337. Italy Indocyanine Green, by End Users USD Million (2023-2028)
  • Table 338. Italy Indocyanine Green, by Route of Administration USD Million (2023-2028)
  • Table 339. United Kingdom Indocyanine Green, by Application USD Million (2023-2028)
  • Table 340. United Kingdom Indocyanine Green, by Dosage Consideration USD Million (2023-2028)
  • Table 341. United Kingdom Indocyanine Green, by End Users USD Million (2023-2028)
  • Table 342. United Kingdom Indocyanine Green, by Route of Administration USD Million (2023-2028)
  • Table 343. Netherlands Indocyanine Green, by Application USD Million (2023-2028)
  • Table 344. Netherlands Indocyanine Green, by Dosage Consideration USD Million (2023-2028)
  • Table 345. Netherlands Indocyanine Green, by End Users USD Million (2023-2028)
  • Table 346. Netherlands Indocyanine Green, by Route of Administration USD Million (2023-2028)
  • Table 347. Rest of Europe Indocyanine Green, by Application USD Million (2023-2028)
  • Table 348. Rest of Europe Indocyanine Green, by Dosage Consideration USD Million (2023-2028)
  • Table 349. Rest of Europe Indocyanine Green, by End Users USD Million (2023-2028)
  • Table 350. Rest of Europe Indocyanine Green, by Route of Administration USD Million (2023-2028)
  • Table 351. MEA Indocyanine Green, by Country USD Million (2023-2028)
  • Table 352. MEA Indocyanine Green, by Application USD Million (2023-2028)
  • Table 353. MEA Indocyanine Green, by Dosage Consideration USD Million (2023-2028)
  • Table 354. MEA Indocyanine Green, by End Users USD Million (2023-2028)
  • Table 355. MEA Indocyanine Green, by Route of Administration USD Million (2023-2028)
  • Table 356. Middle East Indocyanine Green, by Application USD Million (2023-2028)
  • Table 357. Middle East Indocyanine Green, by Dosage Consideration USD Million (2023-2028)
  • Table 358. Middle East Indocyanine Green, by End Users USD Million (2023-2028)
  • Table 359. Middle East Indocyanine Green, by Route of Administration USD Million (2023-2028)
  • Table 360. Africa Indocyanine Green, by Application USD Million (2023-2028)
  • Table 361. Africa Indocyanine Green, by Dosage Consideration USD Million (2023-2028)
  • Table 362. Africa Indocyanine Green, by End Users USD Million (2023-2028)
  • Table 363. Africa Indocyanine Green, by Route of Administration USD Million (2023-2028)
  • Table 364. North America Indocyanine Green, by Country USD Million (2023-2028)
  • Table 365. North America Indocyanine Green, by Application USD Million (2023-2028)
  • Table 366. North America Indocyanine Green, by Dosage Consideration USD Million (2023-2028)
  • Table 367. North America Indocyanine Green, by End Users USD Million (2023-2028)
  • Table 368. North America Indocyanine Green, by Route of Administration USD Million (2023-2028)
  • Table 369. United States Indocyanine Green, by Application USD Million (2023-2028)
  • Table 370. United States Indocyanine Green, by Dosage Consideration USD Million (2023-2028)
  • Table 371. United States Indocyanine Green, by End Users USD Million (2023-2028)
  • Table 372. United States Indocyanine Green, by Route of Administration USD Million (2023-2028)
  • Table 373. Canada Indocyanine Green, by Application USD Million (2023-2028)
  • Table 374. Canada Indocyanine Green, by Dosage Consideration USD Million (2023-2028)
  • Table 375. Canada Indocyanine Green, by End Users USD Million (2023-2028)
  • Table 376. Canada Indocyanine Green, by Route of Administration USD Million (2023-2028)
  • Table 377. Mexico Indocyanine Green, by Application USD Million (2023-2028)
  • Table 378. Mexico Indocyanine Green, by Dosage Consideration USD Million (2023-2028)
  • Table 379. Mexico Indocyanine Green, by End Users USD Million (2023-2028)
  • Table 380. Mexico Indocyanine Green, by Route of Administration USD Million (2023-2028)
  • Table 381. Indocyanine Green Sales: by Application(K Tons)
  • Table 382. Indocyanine Green Sales Ophthalmology , by Region K Tons (2023-2028)
  • Table 383. Indocyanine Green Sales Neurosurgery , by Region K Tons (2023-2028)
  • Table 384. Indocyanine Green Sales Liver Diseases , by Region K Tons (2023-2028)
  • Table 385. Indocyanine Green Sales Others , by Region K Tons (2023-2028)
  • Table 386. Indocyanine Green Sales: by Dosage Consideration(K Tons)
  • Table 387. Indocyanine Green Sales Hepatic Impairment , by Region K Tons (2023-2028)
  • Table 388. Indocyanine Green Sales Renal Impairment , by Region K Tons (2023-2028)
  • Table 389. Indocyanine Green Sales: by End Users(K Tons)
  • Table 390. Indocyanine Green Sales Neonates and Infants , by Region K Tons (2023-2028)
  • Table 391. Indocyanine Green Sales Children , by Region K Tons (2023-2028)
  • Table 392. Indocyanine Green Sales Adults , by Region K Tons (2023-2028)
  • Table 393. Indocyanine Green Sales: by Route of Administration(K Tons)
  • Table 394. Indocyanine Green Sales Intravenous Bolus Injection , by Region K Tons (2023-2028)
  • Table 395. Indocyanine Green Sales Interstitial Cervical Injection , by Region K Tons (2023-2028)
  • Table 396. South America Indocyanine Green Sales, by Country K Tons (2023-2028)
  • Table 397. South America Indocyanine Green Sales, by Application K Tons (2023-2028)
  • Table 398. South America Indocyanine Green Sales, by Dosage Consideration K Tons (2023-2028)
  • Table 399. South America Indocyanine Green Sales, by End Users K Tons (2023-2028)
  • Table 400. South America Indocyanine Green Sales, by Route of Administration K Tons (2023-2028)
  • Table 401. Brazil Indocyanine Green Sales, by Application K Tons (2023-2028)
  • Table 402. Brazil Indocyanine Green Sales, by Dosage Consideration K Tons (2023-2028)
  • Table 403. Brazil Indocyanine Green Sales, by End Users K Tons (2023-2028)
  • Table 404. Brazil Indocyanine Green Sales, by Route of Administration K Tons (2023-2028)
  • Table 405. Argentina Indocyanine Green Sales, by Application K Tons (2023-2028)
  • Table 406. Argentina Indocyanine Green Sales, by Dosage Consideration K Tons (2023-2028)
  • Table 407. Argentina Indocyanine Green Sales, by End Users K Tons (2023-2028)
  • Table 408. Argentina Indocyanine Green Sales, by Route of Administration K Tons (2023-2028)
  • Table 409. Rest of South America Indocyanine Green Sales, by Application K Tons (2023-2028)
  • Table 410. Rest of South America Indocyanine Green Sales, by Dosage Consideration K Tons (2023-2028)
  • Table 411. Rest of South America Indocyanine Green Sales, by End Users K Tons (2023-2028)
  • Table 412. Rest of South America Indocyanine Green Sales, by Route of Administration K Tons (2023-2028)
  • Table 413. Asia Pacific Indocyanine Green Sales, by Country K Tons (2023-2028)
  • Table 414. Asia Pacific Indocyanine Green Sales, by Application K Tons (2023-2028)
  • Table 415. Asia Pacific Indocyanine Green Sales, by Dosage Consideration K Tons (2023-2028)
  • Table 416. Asia Pacific Indocyanine Green Sales, by End Users K Tons (2023-2028)
  • Table 417. Asia Pacific Indocyanine Green Sales, by Route of Administration K Tons (2023-2028)
  • Table 418. China Indocyanine Green Sales, by Application K Tons (2023-2028)
  • Table 419. China Indocyanine Green Sales, by Dosage Consideration K Tons (2023-2028)
  • Table 420. China Indocyanine Green Sales, by End Users K Tons (2023-2028)
  • Table 421. China Indocyanine Green Sales, by Route of Administration K Tons (2023-2028)
  • Table 422. Japan Indocyanine Green Sales, by Application K Tons (2023-2028)
  • Table 423. Japan Indocyanine Green Sales, by Dosage Consideration K Tons (2023-2028)
  • Table 424. Japan Indocyanine Green Sales, by End Users K Tons (2023-2028)
  • Table 425. Japan Indocyanine Green Sales, by Route of Administration K Tons (2023-2028)
  • Table 426. India Indocyanine Green Sales, by Application K Tons (2023-2028)
  • Table 427. India Indocyanine Green Sales, by Dosage Consideration K Tons (2023-2028)
  • Table 428. India Indocyanine Green Sales, by End Users K Tons (2023-2028)
  • Table 429. India Indocyanine Green Sales, by Route of Administration K Tons (2023-2028)
  • Table 430. South Korea Indocyanine Green Sales, by Application K Tons (2023-2028)
  • Table 431. South Korea Indocyanine Green Sales, by Dosage Consideration K Tons (2023-2028)
  • Table 432. South Korea Indocyanine Green Sales, by End Users K Tons (2023-2028)
  • Table 433. South Korea Indocyanine Green Sales, by Route of Administration K Tons (2023-2028)
  • Table 434. Taiwan Indocyanine Green Sales, by Application K Tons (2023-2028)
  • Table 435. Taiwan Indocyanine Green Sales, by Dosage Consideration K Tons (2023-2028)
  • Table 436. Taiwan Indocyanine Green Sales, by End Users K Tons (2023-2028)
  • Table 437. Taiwan Indocyanine Green Sales, by Route of Administration K Tons (2023-2028)
  • Table 438. Australia Indocyanine Green Sales, by Application K Tons (2023-2028)
  • Table 439. Australia Indocyanine Green Sales, by Dosage Consideration K Tons (2023-2028)
  • Table 440. Australia Indocyanine Green Sales, by End Users K Tons (2023-2028)
  • Table 441. Australia Indocyanine Green Sales, by Route of Administration K Tons (2023-2028)
  • Table 442. Rest of Asia-Pacific Indocyanine Green Sales, by Application K Tons (2023-2028)
  • Table 443. Rest of Asia-Pacific Indocyanine Green Sales, by Dosage Consideration K Tons (2023-2028)
  • Table 444. Rest of Asia-Pacific Indocyanine Green Sales, by End Users K Tons (2023-2028)
  • Table 445. Rest of Asia-Pacific Indocyanine Green Sales, by Route of Administration K Tons (2023-2028)
  • Table 446. Europe Indocyanine Green Sales, by Country K Tons (2023-2028)
  • Table 447. Europe Indocyanine Green Sales, by Application K Tons (2023-2028)
  • Table 448. Europe Indocyanine Green Sales, by Dosage Consideration K Tons (2023-2028)
  • Table 449. Europe Indocyanine Green Sales, by End Users K Tons (2023-2028)
  • Table 450. Europe Indocyanine Green Sales, by Route of Administration K Tons (2023-2028)
  • Table 451. Germany Indocyanine Green Sales, by Application K Tons (2023-2028)
  • Table 452. Germany Indocyanine Green Sales, by Dosage Consideration K Tons (2023-2028)
  • Table 453. Germany Indocyanine Green Sales, by End Users K Tons (2023-2028)
  • Table 454. Germany Indocyanine Green Sales, by Route of Administration K Tons (2023-2028)
  • Table 455. France Indocyanine Green Sales, by Application K Tons (2023-2028)
  • Table 456. France Indocyanine Green Sales, by Dosage Consideration K Tons (2023-2028)
  • Table 457. France Indocyanine Green Sales, by End Users K Tons (2023-2028)
  • Table 458. France Indocyanine Green Sales, by Route of Administration K Tons (2023-2028)
  • Table 459. Italy Indocyanine Green Sales, by Application K Tons (2023-2028)
  • Table 460. Italy Indocyanine Green Sales, by Dosage Consideration K Tons (2023-2028)
  • Table 461. Italy Indocyanine Green Sales, by End Users K Tons (2023-2028)
  • Table 462. Italy Indocyanine Green Sales, by Route of Administration K Tons (2023-2028)
  • Table 463. United Kingdom Indocyanine Green Sales, by Application K Tons (2023-2028)
  • Table 464. United Kingdom Indocyanine Green Sales, by Dosage Consideration K Tons (2023-2028)
  • Table 465. United Kingdom Indocyanine Green Sales, by End Users K Tons (2023-2028)
  • Table 466. United Kingdom Indocyanine Green Sales, by Route of Administration K Tons (2023-2028)
  • Table 467. Netherlands Indocyanine Green Sales, by Application K Tons (2023-2028)
  • Table 468. Netherlands Indocyanine Green Sales, by Dosage Consideration K Tons (2023-2028)
  • Table 469. Netherlands Indocyanine Green Sales, by End Users K Tons (2023-2028)
  • Table 470. Netherlands Indocyanine Green Sales, by Route of Administration K Tons (2023-2028)
  • Table 471. Rest of Europe Indocyanine Green Sales, by Application K Tons (2023-2028)
  • Table 472. Rest of Europe Indocyanine Green Sales, by Dosage Consideration K Tons (2023-2028)
  • Table 473. Rest of Europe Indocyanine Green Sales, by End Users K Tons (2023-2028)
  • Table 474. Rest of Europe Indocyanine Green Sales, by Route of Administration K Tons (2023-2028)
  • Table 475. MEA Indocyanine Green Sales, by Country K Tons (2023-2028)
  • Table 476. MEA Indocyanine Green Sales, by Application K Tons (2023-2028)
  • Table 477. MEA Indocyanine Green Sales, by Dosage Consideration K Tons (2023-2028)
  • Table 478. MEA Indocyanine Green Sales, by End Users K Tons (2023-2028)
  • Table 479. MEA Indocyanine Green Sales, by Route of Administration K Tons (2023-2028)
  • Table 480. Middle East Indocyanine Green Sales, by Application K Tons (2023-2028)
  • Table 481. Middle East Indocyanine Green Sales, by Dosage Consideration K Tons (2023-2028)
  • Table 482. Middle East Indocyanine Green Sales, by End Users K Tons (2023-2028)
  • Table 483. Middle East Indocyanine Green Sales, by Route of Administration K Tons (2023-2028)
  • Table 484. Africa Indocyanine Green Sales, by Application K Tons (2023-2028)
  • Table 485. Africa Indocyanine Green Sales, by Dosage Consideration K Tons (2023-2028)
  • Table 486. Africa Indocyanine Green Sales, by End Users K Tons (2023-2028)
  • Table 487. Africa Indocyanine Green Sales, by Route of Administration K Tons (2023-2028)
  • Table 488. North America Indocyanine Green Sales, by Country K Tons (2023-2028)
  • Table 489. North America Indocyanine Green Sales, by Application K Tons (2023-2028)
  • Table 490. North America Indocyanine Green Sales, by Dosage Consideration K Tons (2023-2028)
  • Table 491. North America Indocyanine Green Sales, by End Users K Tons (2023-2028)
  • Table 492. North America Indocyanine Green Sales, by Route of Administration K Tons (2023-2028)
  • Table 493. United States Indocyanine Green Sales, by Application K Tons (2023-2028)
  • Table 494. United States Indocyanine Green Sales, by Dosage Consideration K Tons (2023-2028)
  • Table 495. United States Indocyanine Green Sales, by End Users K Tons (2023-2028)
  • Table 496. United States Indocyanine Green Sales, by Route of Administration K Tons (2023-2028)
  • Table 497. Canada Indocyanine Green Sales, by Application K Tons (2023-2028)
  • Table 498. Canada Indocyanine Green Sales, by Dosage Consideration K Tons (2023-2028)
  • Table 499. Canada Indocyanine Green Sales, by End Users K Tons (2023-2028)
  • Table 500. Canada Indocyanine Green Sales, by Route of Administration K Tons (2023-2028)
  • Table 501. Mexico Indocyanine Green Sales, by Application K Tons (2023-2028)
  • Table 502. Mexico Indocyanine Green Sales, by Dosage Consideration K Tons (2023-2028)
  • Table 503. Mexico Indocyanine Green Sales, by End Users K Tons (2023-2028)
  • Table 504. Mexico Indocyanine Green Sales, by Route of Administration K Tons (2023-2028)
  • Table 505. Research Programs/Design for This Report
  • Table 506. Key Data Information from Secondary Sources
  • Table 507. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Indocyanine Green: by Application USD Million (2018-2023)
  • Figure 5. Global Indocyanine Green: by Dosage Consideration USD Million (2018-2023)
  • Figure 6. Global Indocyanine Green: by End Users USD Million (2018-2023)
  • Figure 7. Global Indocyanine Green: by Route of Administration USD Million (2018-2023)
  • Figure 8. South America Indocyanine Green Share (%), by Country
  • Figure 9. Asia Pacific Indocyanine Green Share (%), by Country
  • Figure 10. Europe Indocyanine Green Share (%), by Country
  • Figure 11. MEA Indocyanine Green Share (%), by Country
  • Figure 12. North America Indocyanine Green Share (%), by Country
  • Figure 13. Global Indocyanine Green: by Application K Tons (2018-2023)
  • Figure 14. Global Indocyanine Green: by Dosage Consideration K Tons (2018-2023)
  • Figure 15. Global Indocyanine Green: by End Users K Tons (2018-2023)
  • Figure 16. Global Indocyanine Green: by Route of Administration K Tons (2018-2023)
  • Figure 17. South America Indocyanine Green Share (%), by Country
  • Figure 18. Asia Pacific Indocyanine Green Share (%), by Country
  • Figure 19. Europe Indocyanine Green Share (%), by Country
  • Figure 20. MEA Indocyanine Green Share (%), by Country
  • Figure 21. North America Indocyanine Green Share (%), by Country
  • Figure 22. Global Indocyanine Green share by Players 2023 (%)
  • Figure 23. Global Indocyanine Green share by Players (Top 3) 2023(%)
  • Figure 24. Global Indocyanine Green share by Players (Top 5) 2023(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. Akorn, Incorporated (United States) Revenue, Net Income and Gross profit
  • Figure 27. Akorn, Incorporated (United States) Revenue: by Geography 2023
  • Figure 28. Aurolab (India) Revenue, Net Income and Gross profit
  • Figure 29. Aurolab (India) Revenue: by Geography 2023
  • Figure 30. SERB (Belgium) Revenue, Net Income and Gross profit
  • Figure 31. SERB (Belgium) Revenue: by Geography 2023
  • Figure 32. Diagnostic Green GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 33. Diagnostic Green GmbH (Germany) Revenue: by Geography 2023
  • Figure 34. Daiichi Sankyo Company, Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 35. Daiichi Sankyo Company, Limited (Japan) Revenue: by Geography 2023
  • Figure 36. Sigma-Aldrich Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 37. Sigma-Aldrich Corporation (United States) Revenue: by Geography 2023
  • Figure 38. Iris Biotech GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 39. Iris Biotech GmbH (Germany) Revenue: by Geography 2023
  • Figure 40. Pulsion Medical Systems (Germany) Revenue, Net Income and Gross profit
  • Figure 41. Pulsion Medical Systems (Germany) Revenue: by Geography 2023
  • Figure 42. Global Indocyanine Green: by Application USD Million (2023-2028)
  • Figure 43. Global Indocyanine Green: by Dosage Consideration USD Million (2023-2028)
  • Figure 44. Global Indocyanine Green: by End Users USD Million (2023-2028)
  • Figure 45. Global Indocyanine Green: by Route of Administration USD Million (2023-2028)
  • Figure 46. South America Indocyanine Green Share (%), by Country
  • Figure 47. Asia Pacific Indocyanine Green Share (%), by Country
  • Figure 48. Europe Indocyanine Green Share (%), by Country
  • Figure 49. MEA Indocyanine Green Share (%), by Country
  • Figure 50. North America Indocyanine Green Share (%), by Country
  • Figure 51. Global Indocyanine Green: by Application K Tons (2023-2028)
  • Figure 52. Global Indocyanine Green: by Dosage Consideration K Tons (2023-2028)
  • Figure 53. Global Indocyanine Green: by End Users K Tons (2023-2028)
  • Figure 54. Global Indocyanine Green: by Route of Administration K Tons (2023-2028)
  • Figure 55. South America Indocyanine Green Share (%), by Country
  • Figure 56. Asia Pacific Indocyanine Green Share (%), by Country
  • Figure 57. Europe Indocyanine Green Share (%), by Country
  • Figure 58. MEA Indocyanine Green Share (%), by Country
  • Figure 59. North America Indocyanine Green Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Akorn, Incorporated (United States)
  • Aurolab (India)
  • SERB (Belgium)
  • Diagnostic Green GmbH (Germany)
  • Daiichi Sankyo Company, Limited (Japan)
  • Sigma-Aldrich Corporation (United States)
  • Iris Biotech GmbH (Germany)
  • Pulsion Medical Systems (Germany)
Additional players considered in the study are as follows:
H.W. Sands Corp (United States) , Dandong Yichuang Pharmaceutical Co., Ltd. (China)
Select User Access Type

Key Highlights of Report


Apr 2024 243 Pages 54 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Indocyanine Green Quantitative research analysis
Global Indocyanine Green Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Indocyanine Green market are Akorn, Incorporated (United States), Aurolab (India), SERB (Belgium), Diagnostic Green GmbH (Germany), Daiichi Sankyo Company, Limited (Japan), Sigma-Aldrich Corporation (United States), Iris Biotech GmbH (Germany) and Pulsion Medical Systems (Germany), to name a few.
is dominating the Indocyanine Green Market.
"" is seen as one of the major challenges by many Industry Players of Indocyanine Green Market
The Indocyanine Green market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Indocyanine Green market is expected to see a steady growth rate during projected year 2023 to 2028.

Know More About Global Indocyanine Green Report?

Have a Query? Click Here

Other Related Reports

Drug Delivery Comprehensive Study by Application (Hospital Pharmacies, Pharmacy Stores, Direct Tenders, Online Pharmacy), Route of Administration (Oral Drug Delivery, Injectable Drug Delivery, Topica...
$ 3750
Nicotine Polacrilex Comprehensive Study by Type (High Purity, Low Purity), Application (Nicotine Polacrilex Gum, Nicotine Polacrilex Lozenge, Other), Distribution Channel (Brick and Mortar Drug Store...
$ 3650
Melanoma Drugs Comprehensive Study by Application (Hospitals, Clinics, Other), Therapy (Chemotherapy, Immuno-therapy, Targeted Therapy, Radiation Therapy) Players and Region - Global Market Outlook t...
$ 3500
Neuromyelitis Optica Drug Comprehensive Study by Type (Glucocorticoids, Immunoglobulin), Application (Acute Attack, Remission Prophylactic treatment), Product Type (Production Share, Price Rage, Cost...
$ 3500
Protein Therapeutic Comprehensive Study by Type (Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone), Application (Cancer, ...
$ 3750
Pet Ear Care Products Comprehensive Study by Type (Ear Cleansing Solution (Medicated, OTC (Over the Counter)), Ear Cleaner Wipes, Others), Application (Dogs, Cats, Others), Sales Channel (Online Sale...
$ 3500